← Back to Search

Clinical Decision Support Algorithm

Decision Support for Antibiotic Selection in Sepsis (IDEAS-CRXO Trial)

N/A

Recruiting

Research Sponsored by Ottawa Hospital Research Institute

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

I. Vancomycin II. Linezolid III. Daptomycin IV. Cefazolin V. Cloxacillin VI. Ceftriaxone VII. Ceftazidime VIII. Piperacillin-Tazobactam IX. Meropenem (or Imipenem or Ertapenem) X. Ciprofloxacin (or Moxifloxacin or Levofloxacin) XI. Gentamicin (or Tobramycin).

Age >18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 90 days

Awards & highlights

No Placebo-Only Group

Summary

This trial aims to help clinicians choose the right antibiotics for patients with sepsis, a severe infection. The goal is to balance between giving effective treatment and avoiding unnecessary antibiotics that can lead to resistance.

Who is the study for?

This trial is for hospitalized adults over 18 years old with suspected sepsis who have had blood cultures ordered within 12 hours before or after starting antibiotics. It's not suitable for those allergic to the listed antibiotics like Vancomycin, Linezolid, and others.

What is being tested?

The study tests a clinical decision support algorithm designed to help doctors choose the right empiric antibiotic therapy for sepsis patients. The goal is to balance treatment effectiveness with antibiotic stewardship to prevent resistance.

What are the potential side effects?

Since this trial focuses on decision-making rather than new drugs, side effects relate to existing antibiotics used in practice and may include allergic reactions, gastrointestinal issues, kidney damage, or development of resistance.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am not allergic to common antibiotics like Vancomycin, Ciprofloxacin, or Gentamicin.

Select...

I am older than 18 years.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 90 days

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~90 days

This trial's timeline: 3 weeks for screening, Varies for treatment, and 90 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Number of Patients De-escalated

Secondary study objectives

Antibiotic spectrum at completion

Days of antibiotic therapy

De-escalation extent

+15 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Clinical Decision Support Algorithm for Empiric Antibiotics in SepsisExperimental Treatment1 Intervention

The planned intervention consists of a pharmacist-facilitated clinical decision support intervention, where pharmacists provide options and recommendations on empiric sepsis antibiotic selection to hospital providers.

Group II: Standard of CareActive Control1 Intervention

Non-intervention group. No decision support is provided. Patient care is routine.

0 / 2Eligibility criteria met